# Nitinotes

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nitinotes

- Industry: Medical Devices & Equipment
- Headquarters: Israel
- Website: www.nitinotesurgical.com
- Total disclosed funding: $7.1M
- Latest round: Series A (May 10, 2020)
- Investors on record: 5

## About

Nitinotes LTD is a medical technology firm focusing on innovative endoscopic solutions, particularly the EndoZip™, which enhances minimally invasive surgery for obesity treatment.Nitinotes LTD specializes in automated endoscopic solutions, particularly the EndoZip™ system. Founded in 2014 in Israel, the company has completed a total of 4 deals. The latest funding round raised USD 0.673 mn and was led by the Israel Innovation Authority. The company’s CEO is Raz Bar-On.Nitinotes Surgical's primary offering is the EndoZip™, an automated endoscopic suturing system designed to facilitate endoscopic gastroplasty procedures for the treatment of obesity. This innovative device streamlines the process of delivering restrictive sutures to the stomach wall, making it a minimally invasive option for patients with obesity class I & II who do not qualify for traditional bariatric surgery. The EndoZip™ has been validated through clinical studies, demonstrating a high safety profile and significant total body weight loss (TBWL) results, with patients averaging 13.5% TBWL over 12 months post-procedure. Nitinotes operates on a global scale, with its products already being tested and implemented across various sites in Europe, including multi-center studies in Spain, Italy, and Israel, targeting over 700 million individuals suffering from obesity.Nitinotes Surgical generates revenue primarily through the sales of the EndoZip™ system to healthcare facilities and medical practitioners specializing in obesity treatment. Transactions typically occur on a business-to-business (B2B) basis, with hospitals and clinics purchasing the device for use in their endoscopic procedures. The pricing structure is designed to accommodate healthcare providers, allowing them to integrate the EndoZip™ into their offerings for patients seeking effective obesity solutions. Additionally, the company may explore partnerships with key opinion leaders in the bariatric field, further driving adoption and expanding their market reach. The EndoZip™ is positioned as the flagship product, with potential for ongoing revenue from supplementary training and support services associated with its implementation in clinical settings.Nitinotes LTD plans to leverage recent funding of ILS 1 million raised from Accelmed to enhance its product offerings and expand its market presence. The company is focused on launching additional products designed for the obesity treatment market and aims to penetrate new geographic regions. Specific target markets for expansion include additional European countries and potential entry into North American markets, with plans to initiate these efforts within the next 18 months.

## Funding rounds

- Series A, May 10, 2020, $7.1M — Peregrine Ventures, Accelmed, MTIP, Techwald Holding, Elron Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series A
- Accelmed (https://capitalatlas.ai/funds/accelmed) — Series A
- MTIP (https://capitalatlas.ai/funds/mtip) — Series A
- Techwald Holding (https://capitalatlas.ai/funds/techwald-holding) — Series A
- Elron Ventures (https://capitalatlas.ai/funds/elron-ventures) — Series A